Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

WOK vs MTVA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

MTVA Captures Overall Composite Edge (48.0 HOLD vs 31.4 SELL), While WOK Leads 4–1 on Growth & Valuation Pillars

MTVA Overall Winner 6-Pillar Tally: WOK 4 – 1 MTVA (1 Tie) Matrix Metrics: WOK 4 – 3 MTVA

As of Nov 20, 2026, MetaVia Inc. (MTVA) captures the overall head-to-head institutional edge over WORK Medical Technology Group LTD Class A (WOK) on higher Unified Composite conviction (48.0/100 HOLD vs. 31.4/100 SELL) after splitting the core matrix 3–4 (led by Profitability & Quality), while WOK wins 4–1 across the 6-pillar growth and valuation breakdown. WOK trades at $1.10 (N/M Forward P/E, -41.7% operating margin) versus MTVA at $1.01 (N/M Forward P/E, 0.0% operating margin).

  • Growth vs. Quality Trade-Off: MTVA earns the overall head-to-head edge with a stronger Unified Composite Score (48.0/100 HOLD vs. WOK 31.4/100 SELL) and 1.30β · 166% Vol risk profile, whereas WOK leads top-line expansion (+19.1% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: WOK is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 42.8); meanwhile MTVA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 38.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About WOK vs MTVA
WOK NASDAQ
WORK Medical Technology Group LTD Class A Ordinary Shares
Surgical & Medical Instruments & Apparatus
$1.10
-5.13% 1D
Market Cap $5.2M
TTM Revenue $11M
Forward P/E N/M
Beta / 30D Vol 37.03β · 149% Vol
Unified Composite Score
31.4 / 100 SELL
Tech 15.0 Fund 34.0 Flow 50.0 Mom 44.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -23.0%), weak momentum, RSI 43
RSI-14: 42.8 · SMA20: $1.13 · SMA50: $1.40
MTVA NASDAQ Head-to-Head Winner
MetaVia Inc. Common Stock
Pharmaceutical Preparations
$1.01
-5.61% 1D
Market Cap $7.2M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.30β · 166% Vol
Unified Composite Score
48.0 / 100 HOLD
Tech 40.0 Fund 60.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -10.2%), weak momentum, RSI 38
RSI-14: 38.1 · SMA20: $1.24 · SMA50: $1.40

6-Pillar Scorecard Institutional Category Breakdown (WOK 4 – 1 MTVA)

Columns: Metric · WOK · MTVA
1. Valuation Multiples WOK
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 0.5x N/M
2. Growth & Scale WOK
Revenue Growth (YoY) +19.1% +0.0%
Earnings Growth (YoY) -95.0% +0.0%
TTM Revenue (USD) $11M N/A
Market Cap $5.2M $7.2M
3. Profitability & Quality MTVA
Gross Margin 17.0% N/A
Operating Margin -41.7% 0.0%
Net Profit Margin -41.9% 0.0%
Return on Equity (ROE) -19.2% -175.7%
4. Balance Sheet & Cash Flow WOK
Cash Generation (TTM) -$3.4M EBITDA -$15M
Cash Flow Margin -31.4% EBITDA Mgn N/A
Net Cash / Leverage $1855.16 Book/Sh · -19.2% ROE $14M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat WOK
OpEx & R&D Intensity 58.7% of Rev ($6.3M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: WOK (4) vs MTVA (3)
Institutional Metric WOK MTVA Criterion Row Edge
Market Capitalization
Scale
$5.2M $7.2M Larger Scale Tie
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+19.1% +0.0% Higher Growth WOK
Operating Margin (TTM)
Profitability
-41.7% 0.0% Higher Margin MTVA
Net Profit Margin
Profitability
-41.9% 0.0% Higher Margin MTVA
Return on Equity (ROE)
Capital Efficiency
-19.2% -175.7% Higher ROE WOK
52-Week Range Position
Momentum
14% ($0–$7) 4% ($1–$13) Stronger Trend WOK
Beta / 30D Volatility
Risk Regime
37.03β · 149% Vol 1.30β · 166% Vol Lower Realized Risk WOK
Unified Institutional Score
Composite Signal
31.4 / 100 (SELL) 48.0 / 100 (HOLD) Higher Composite MTVA
Trailing 12M Revenue (USD)
Operating Scale
$11M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
17.0% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.5x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$3.4M EBITDA ($1855.16 Book/Sh · -19.2% ROE) -$15M ($14M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon WOK +24.3 pp
WOK: -3.04% · MTVA: -27.34%
3M Horizon MTVA +16.65 pp
WOK: -50.64% · MTVA: -33.99%
6M Horizon WOK +952.95 pp
WOK: +879.18% · MTVA: -73.77%
1Y Horizon MTVA +104.46 pp
WOK: -72.26% · MTVA: +32.2%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on WOK vs MTVA. Trailing 12-month operating profitability (WOK -41.7% vs MTVA 0.0%) and valuation multiples (WOK N/M vs MTVA N/M Forward P/E) are benchmarked directly in Pillar 4 below.

WOK ADR TTM Benchmark FX-Normalized USD
TTM Revenue$11M
Gross Margin17.0%
Op. Margin-41.7%
ROE / Fwd P/E-19.2% · N/M
MTVA ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-175.7% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
WOK UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact WOK Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
MTVA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact MTVA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
WOK Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $5.2M market capitalization and -41.7% operating margin.
OpEx & R&D Reinvestment 58.7% of Rev ($6.3M)
90D Engineering Disclosures 0 Published
MTVA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $7.2M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ WOK vs MTVA Key Questions & Quantitative Answers

As of Nov 20, 2026, MetaVia Inc. (MTVA) captures the overall head-to-head institutional edge over WORK Medical Technology Group LTD Class A (WOK) on higher Unified Composite conviction (48.0/100 HOLD vs. 31.4/100 SELL) after splitting the core matrix 3–4 (led by Profitability & Quality), while WOK wins 4–1 across the 6-pillar growth and valuation breakdown. WOK trades at $1.10 (N/M Forward P/E, -41.7% operating margin) versus MTVA at $1.01 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: MTVA earns the overall head-to-head edge with a stronger Unified Composite Score (48.0/100 HOLD vs. WOK 31.4/100 SELL) and 1.30β · 166% Vol risk profile, whereas WOK leads top-line expansion (+19.1% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: WOK is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 42.8); meanwhile MTVA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 38.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

WOK leads the Growth & Scale pillar: WOK posts +19.1% YoY revenue growth and -95.0% YoY earnings growth on $11M TTM revenue (17.0% gross margin, -41.7% operating margin), compared with MTVA at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, WOK generates $11M in USD-normalized revenue versus N/A for MTVA. In operating R&D and SG&A reinvestment, WOK deploys 58.7% of Rev ($6.3M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MTVA.

WOK screens cheaper on headline valuation multiples. WOK trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.5x EV/Revenue (-31.4% EBITDA margin), whereas MTVA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against WOK (-19.2% ROE) versus MTVA (-175.7% ROE) capital efficiency.

In options market volatility and institutional positioning, WOK carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (37.03β · 149% Vol realized risk). By comparison, MTVA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.30β · 166% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.